Why Jade Biosciences, Inc.’s (JBIO) Stock Is Down 6.80%
As of Wednesday, September 23, Jade Biosciences, Inc.’s JBIO share price has dipped by 6.80%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Commentary & Analysis
Why Jade Biosciences, Inc.’s (JBIO) Stock Is Down 10.02%
As of Wednesday, September 23, Jade Biosciences, Inc.’s JBIO share price has dipped by 10.02%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Jade Biosciences, Inc.’s (JBIO) Stock Is Up 5.14%
As of Thursday, September 17, Jade Biosciences, Inc.’s JBIO share price has surged by 5.14%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Jade Biosciences, Inc.’s (JBIO) Stock Is Down 6.68%
As of Thursday, September 03, Jade Biosciences, Inc.’s JBIO share price has dipped by 6.68%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Jade Biosciences, Inc.’s (JBIO) Stock Is Up 6.22%
As of Friday, August 21, Jade Biosciences, Inc.’s JBIO share price has surged by 6.22%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | JBIO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,065.9 | $271.9 | 46% |
|
| Shares Out (Mil) | 61.1 | 54.2 | 52% |
|
| Institutional Ownership | 99.7% | 92.9% | 92% |
|
| Float (Mil) | 52.0 | 42.1 | 48% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 1,232 | 612 | 72% |
|
| Price Change (52-week) |
125.9% | 56.0% | 95% |
|
| Growth | JBIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.7% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.786) | ($2.932) | ($2.663) | |
| Month Ago EPS | ($0.786) | ($2.932) | ($2.663) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 2 | 0 | 0 | |
| Three Months Ago EPS | ($0.565) | ($2.282) | ($2.280) | |
| Year/Year Chg | 3.8% | (8.2%) | (26.7%) | |
| Financials | JBIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($153) | ($43) | 8% |
|
| EPS (TTM) | ($2.343) | ($1.500) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($124) | ($32) | 5% |
|
| Net Cash Flow (TTM) (Mil) | ($114) | $2 | 13% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 15% |
|
| Enterprise Value (Q1) (Mil) | $605 | $177 | 36% |
|
| Valuation | JBIO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.42 | 2.67 | 58% |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | JBIO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.0% | na |
|
| Net Margin | na | (71.5%) | na |
|
| ROA | (44.0%) | (47.4%) | 13% |
|
| ROE | (47.8%) | (54.6%) | 16% |
|
| Liabilities to Assets | 6.8% | 29.3% | 4% |
|
| F-Score | 2 | 3 | na |
|
Jade Biosciences, Inc. did not pass any screens on 9/22/2026.
